Table 3.

Assessment of advice provided to simulated new contraceptive pill users according to type of PPMV (based on Fisher’s exact test at 0.05 significance level)

	PPMV owner	PPMV attendant	P-value
New pill users (N=184)	(N=150)	(N=34)
Prescribed or sold pills	59 (39.3%)	16 (47.1%)	0.443
Referred to higher level	43 (28.7%)	13 (38.2%)	0.304
Advised on what to do when they miss a pill	36 (24.0%)	8 (23.5%)	0.575
Asked if ever used any method of contraception	50 (33.3%)	9 (26.5%)	0.288
Possible side effects mentioned	26 (17.3%)	2 (5.9%)	0.115
Advised on how to manage side effects	13 (8.7%)	1 (2.9%)	0.472
	Male	Female	P-value
New pill users (N=184)	(N=165)	(N=19)
Prescribed or sold pills	71 (43%)	4 (21.0%)	0.085
Referred to higher level	49 (30.8%)	7 (50.0%)	0.149
Advised on what to do when they miss a pill	44 (26.7%)	0 (0.0%)	0.008*
Asked if ever used any method of contraception	55 (33.3%)	4 (21.1%)	0.436
Possible side effects mentioned	28 (17.0%)	0 (0.0%)	0.083
Advised on how to manage side effects	0 (0.0%)	14 (8.5%)	0.368
	English	Local languages	P-value
New pill users (N=169)	(N=108)	(N=61)
Prescribed or sold pills	53 (49.1%)	14 (23%)	0.001*
Referred to higher level	28 (28.3%)	24 (40%)	0.163
Advised on what to do when they miss a pill	31 (28.7%)	9 (14.8%)	0.059
Asked if ever used any method of contraception	35 (32.4%)	13 (21.3%)	0.156
Possible side effects mentioned	18 (16.7%)	5 (8.2%)	0.162
Advised on how to manage side effects	7 (6.5)	4 (6.6%)	1.000

Note:

^*Significant at a=0.05.

Abbreviation: PPMV, proprietary patent medicine vendors.